Generic User Fee Hikes Could Disrupt US FDA Drug Pricing Campaign
New GDUFA program fee is high enough that sponsors may withdraw applications to reduce their fee exposure, agency estimates.
You may also be interested in...
US Generic drug approvals drop in July, but still are above the monthly average for the year, potentially signaling a new expected output.
Prioritizing ANDAs entering markets with fewer than three approved generics not expected to become a major advantage until first-cycle clearances increase.
Nearly 2,000 ANDAs remain unclaimed as US FDA begins fee calculations for GDUFA II.